It can reduce involuntary movements and help control motor fluctuations, although treatment requires careful attention to kidney function, mental health effects, and withdrawal symptoms. Amantadine is used for Parkinson’s disease symptoms and selected drug-induced movement problems, with its main benefit linked to reducing dyskinesia.
Amantadine, the active substance in Amantadine, is an antiviral-derived neurological medicine used in Parkinson’s disease and drug-induced extrapyramidal symptoms.
Amantadine is used in Parkinson’s disease to reduce motor symptoms such as dyskinesia, stiffness, tremor, and periods when levodopa appears to wear off. It may also be prescribed for drug-induced extrapyramidal symptoms, including movement problems caused by some dopamine-blocking medicines.
Treatment is usually planned by a clinician familiar with movement disorders. Amantadine may be used alone in selected situations, though it is often added to an established Parkinson’s regimen when involuntary movements or fluctuating mobility become difficult to control.
Amantadine may help with:
The medicine does not restore lost dopamine-producing nerve cells. Its role is symptom control. NICE guidance for Parkinson’s disease recognises amantadine as an option for dyskinesia when movement complications affect daily activities [1].
Clinical response varies. Some people notice fewer involuntary movements, while others experience limited benefit or stop treatment because of dizziness, confusion, ankle swelling, or sleep disturbance.
Amantadine has several effects in the central nervous system. Its anti-dyskinetic action is linked mainly to modulation of glutamate signalling through the N-methyl-D-aspartate, or NMDA, receptor. Glutamate is a major excitatory neurotransmitter involved in motor control and abnormal movement patterns.
Amantadine also has dopaminergic effects. It may increase dopamine release and reduce dopamine reuptake, though these actions do not fully explain its benefit against levodopa-related dyskinesia. The combined effect can make motor signalling less excessively stimulated in vulnerable brain pathways.
Parkinson’s disease reduces dopamine activity in circuits that coordinate movement. Levodopa replaces some of that dopamine activity, but long-term treatment can produce uneven stimulation. That uneven signalling may contribute to dyskinesia and wearing-off.
Amantadine appears to reduce excessive glutamatergic activity in these motor circuits. The result may be fewer involuntary movements without removing the mobility benefit provided by levodopa.
The anti-dyskinetic response may fade with time. A person can improve initially and later notice that the same regimen has less impact. This does not automatically mean the medicine should be stopped abruptly.
Amantadine is classified as an antiparkinsonian medicine with dopaminergic and NMDA-receptor effects.
Amantadine is not suitable for everyone. This medication is not for you if a clinician has identified a serious reason to avoid it, including:
Pregnancy and breastfeeding require an individual assessment because neurological symptoms, maternal health, and infant exposure all affect the decision.
Amantadine can interact with medicines that influence the nervous system or heart rhythm. The clinical team should know about:
This medication is not for you if a clinician has identified a serious reason to avoid it, including severe kidney problems, a previous serious allergic reaction to amantadine, uncontrolled seizures, severe untreated heart failure, active psychosis, or a condition in which confusion or hallucinations would be dangerous.
Speak with a clinician before use if you are pregnant or breastfeeding, have kidney disease, or take medicines for Parkinson’s disease, blood pressure, mood, sleep, or heart rhythm.
Common or clinically relevant adverse effects include:
The risk of confusion and hallucinations rises in older adults, people with Parkinson’s disease dementia, and those with impaired kidney function. Amantadine can also worsen orthostatic hypotension, which means a fall in blood pressure after standing.
Livedo reticularis is often painless but should be reported because it may be linked with fluid retention or other circulatory effects. Ankle swelling can also appear gradually and may be easy to overlook if it is not checked during routine care.
Serious reactions require prompt medical attention. These include severe confusion, marked behavioural change, inability to pass urine, fainting, seizures, severe breathlessness, or rapidly worsening swelling.
A patient may sleep badly after starting treatment. Taking a later dose too close to bedtime can make insomnia more troublesome, though the schedule must remain consistent with the prescribed regimen.
Combining medicines with anticholinergic effects may increase dry mouth, blurred vision, constipation, urinary retention, confusion, or hallucinations. Alcohol can add to dizziness and impaired judgement.
Amantadine is the active substance in this medicine. It is an antiviral-derived neurological medicine used for Parkinson’s disease and selected drug-induced extrapyramidal symptoms. The strength-specific regimen is confirmed with a healthcare professional before treatment starts.
One practical detail is often missed: kidney function has a major effect on amantadine clearance. Older adults and people with reduced renal function may need a lower regimen or longer intervals between doses.
Dose selection may need adjustment for:
The regimen for the chosen strength should be confirmed with a healthcare professional before treatment begins.
A taper is usually planned rather than an abrupt stop. The exact reduction depends on the regimen, treatment duration, kidney function, and the other Parkinson’s medicines being taken.
The BNF identifies renal function as a key factor when determining amantadine dosing and monitoring [2].
Amantadine and levodopa work through different pharmacological pathways. Levodopa is converted into dopamine in the brain, while amantadine modulates glutamate signalling and may influence dopaminergic transmission.
| Treatment approach | Main purpose | Main limitation |
|---|---|---|
| Levodopa-based treatment | Improve slowness, rigidity, and mobility | May cause motor fluctuations or dyskinesia over time |
| Amantadine added to levodopa | Reduce dyskinesia and smooth motor complications | May cause confusion, hallucinations, ankle swelling, or insomnia |
| Amantadine without levodopa | Selected symptom-control situations | May provide less benefit for established motor disability |
Specialist protocols, including material associated with Seoul National University Hospital, illustrate how amantadine can be incorporated into treatment plans for Parkinson’s motor complications. The final regimen still depends on the person’s symptoms, cognition, renal function, and response to levodopa.
Poor outcomes often arise from practical errors rather than a complete lack of drug activity.
One subtle error is changing several Parkinson’s medicines at once. If symptoms improve or worsen, the prescriber then has difficulty identifying which change caused the result.
Another is judging the treatment after a single difficult day. Dyskinesia, sleep, hydration, constipation, infection, and stress can all alter motor performance. A short symptom record gives a clearer clinical picture. Patterns across several days are more reliable. Share the record at follow-up.
In clinical practice, doctors usually view Amantadine as a targeted treatment for dyskinesia and selected motor complications rather than a universal Parkinson’s medicine. The benefit is judged by movement diaries, walking safety, daily function, and the patient’s ability to carry out ordinary tasks.
A neurologist will often ask whether involuntary movements occur after levodopa, during medication “on” periods, or when a dose is wearing off. That timing helps distinguish dyskinesia from tremor, dystonia, freezing, and medication wearing off.
The main clinical trade-off is clear: amantadine may reduce dyskinesia, but it can worsen hallucinations, confusion, insomnia, ankle swelling, or balance. The treatment plan must account for cognition and kidney function, not only movement symptoms.
The WHO’s neurological medicine principles emphasise individualised treatment and monitoring when medicines affect central nervous system function [3]. A stable dose can still become excessive if renal function declines.
The effect of one dose varies with renal function, the prescribed schedule, and the person’s Parkinson’s symptoms. Amantadine has an elimination half-life of about 10 to 14 hours in adults with normal kidney function, but the clinical benefit does not follow a precise clock. NICE guidance reviewed in 2017 describes amantadine as an option for Parkinson’s dyskinesia, with treatment response assessed individually . Worsening symptoms before the next dose should be recorded rather than corrected with an unscheduled extra pill.
Amantadine pills can generally be taken with food or without food, provided the timing remains consistent. Taking a dose with food may be more comfortable if nausea occurs, while a late dose may worsen insomnia. The MHRA’s medicine-safety approach in 2024 continued to support practical monitoring of central nervous system adverse effects and medicine timing. A sudden change in meal timing is less important than avoiding missed or doubled doses.
Amantadine is sometimes combined with levodopa and other Parkinson’s medicines, but the combination can increase dizziness, confusion, hallucinations, or involuntary movements. Anticholinergic medicines, sedating products, stimulants, blood-pressure medicines, and drugs that affect kidney function also need review. The EMA’s pharmacovigilance principles in 2023 required clinicians to consider cumulative effects when several medicines act on the brain or cardiovascular system. Herbal supplements should also be disclosed, especially products marketed for sleep, energy, or mood.
Use in people under 18 depends on the diagnosis, formulation, kidney function, and specialist assessment. Parkinson’s disease is uncommon in children, while drug-induced movement disorders require evaluation of the medicine that caused them. WHO paediatric-medicine principles published in 2022 support weight, age, and organ-function-based prescribing rather than automatically applying adult schedules. A 100 mg pill should not be divided or assigned to a child without a specific clinical plan.
Stopping suddenly can cause worsening tremor, stiffness, gait disturbance, weakness, pain, dyskinesia, or wearing off. Confusion, agitation, and delirium are also possible, especially after long-term treatment or in advanced Parkinson’s disease. NICE guidance updated in 2024 continues to support planned medication review when Parkinson’s symptoms change, while the MHRA highlights the need for vigilance around neurological adverse effects. A taper is commonly considered, with the schedule determined by the prescriber rather than by changing doses independently.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The involuntary movements after my morning levodopa were less obvious by the third week. I still had some dizziness when standing, so I became more careful on stairs. Sleep was acceptable when I avoided taking the tablet late.
Walking felt smoother at first and my wife noticed fewer twisting movements. I then developed vivid dreams and mild ankle swelling. The dose was reviewed rather than stopped suddenly, and the swelling improved after the change.
I did not notice much change in my stiffness during the first fortnight. My mouth felt dry and I had trouble getting to sleep. The medicine was easier to manage once the timing was changed, but the benefit remained modest.
The treatment helped shorten the periods when my movements became difficult, especially late in the day. I missed doses during a weekend away and felt much more rigid and weak. The symptoms settled after my regular schedule was restored.
